Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 58
- Registration Number
- NCT00834379
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Granisetron 1 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00834717
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Famciclovir 500 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT00834444
- Locations
- 🇨🇦
Ba Research Co., Toronto, Ontario, Canada
🇺🇸Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Ribavirin 200 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 27
- Registration Number
- NCT00835536
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
🇺🇸Bioassay Laboratory, Inc., Houston, Texas, United States
Venlafaxine 25 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00834964
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Cefdinir Capsules 300 mg, Non-fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00834535
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00834197
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00834873
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Cefadroxil 500 mg Capsules Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 26
- Registration Number
- NCT00834275
- Locations
- 🇺🇸
Bioassay Laboratory, Inc., Houston, Texas, United States
🇨🇦Biovail Contract Research, Toronto, Ontario, Canada
Azithromycin 600 Mg Tablets, Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT00834756
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath